Short answer
NeuroPace Inc (NPCE) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results released for quarter ended June 30, 2026.
NeuroPace Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results released for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains financial results and investor-relevant operating details
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $22.8M, up 17%; RNS revenue $22.5M, up 21.3%, signaling continued adoption in focal epilepsy
- Net loss narrowed to $6.2M from $10.0M; Adjusted EBITDA loss improved to $2.8M from $4.9M
- 2026 revenue guidance raised to $99.5M–$101.5M, with RNS growth outlook maintained at 21%–23%
- Adjusted EBITDA guidance improved to a $7.5M–$8.5M loss; non-GAAP gross margin raised to 82.0%–83.0%
- FDA engagement for IGE expansion remains on track, supported by 24-month NAUTILUS data showing 100% median GTC seizure reductionેણ
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other NeuroPace Inc 8-K filings
Get the next NPCE 8-K as it lands
Follow NPCE for push alerts, or ask the research agent what this filing means.